These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 22335515)

  • 1. New perspectives in antiplatelet therapy.
    Tello-Montoliu A; Jover E; Rivera J; Valdés M; Angiolillo DJ; Marín F
    Curr Med Chem; 2012; 19(3):406-27. PubMed ID: 22335515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in antiplatelet therapy.
    Michelson AD
    Hematology Am Soc Hematol Educ Program; 2011; 2011():62-9. PubMed ID: 22160013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet receptors as therapeutic targets: Past, present and future.
    Jamasbi J; Ayabe K; Goto S; Nieswandt B; Peter K; Siess W
    Thromb Haemost; 2017 Jun; 117(7):1249-1257. PubMed ID: 28597906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Antiplatelet agents].
    Steg G
    Bull Acad Natl Med; 2013 Feb; 197(2):375-87; discussion 387-8. PubMed ID: 24919367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute and long-term antiplatelet therapy.
    Papathanasiou AI; Goudevenos JA; Mikhailidis DP; Tselepis AD
    Drugs Today (Barc); 2008 May; 44(5):331-52. PubMed ID: 18548136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis.
    Jennings LK
    Thromb Haemost; 2009 Aug; 102(2):248-57. PubMed ID: 19652875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral antiplatelet therapy for atherothrombotic disease: current evidence and new directions.
    White HD
    Am Heart J; 2011 Mar; 161(3):450-61. PubMed ID: 21392598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet thrombin receptor antagonism and atherothrombosis.
    Angiolillo DJ; Capodanno D; Goto S
    Eur Heart J; 2010 Jan; 31(1):17-28. PubMed ID: 19948715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protease-Activated Receptor 1 Inhibitors: Novel Antiplatelet Drugs in Prevention of Atherothrombosis.
    Al-Khafaji K; Mutyala M; Al-Khafaji N; Harper Y; Ismail I; Hakim H; Arora RR
    Am J Ther; 2017; 24(6):e730-e736. PubMed ID: 26398717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiplatelet drugs in cardiological practice: established strategies and new developments.
    Krötz F; Sohn HY; Klauss V
    Vasc Health Risk Manag; 2008; 4(3):637-45. PubMed ID: 18827913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination antiplatelet treatment in coronary artery disease patients: A necessary evil or an overzealous practice?
    Alexopoulos D; Katogiannis K; Sfantou D; Lekakis J
    Platelets; 2018 May; 29(3):228-237. PubMed ID: 29022423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Mechanisms of platelet activation and development of antiplatelet agents].
    Cazenave JP; Gachet C; Lanza F
    Arch Mal Coeur Vaiss; 1996 Nov; 89(11 Suppl):1501-6. PubMed ID: 9092410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses.
    Judge HM; Buckland RJ; Holgate CE; Storey RF
    Platelets; 2005 Nov; 16(7):398-407. PubMed ID: 16236601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of a novel function-blocking antibody targeted against the platelet P2Y1 receptor.
    Karim ZA; Vemana HP; Alshbool FZ; Lin OA; Alshehri AM; Javaherizadeh P; Paez Espinosa EV; Khasawneh FT
    Arterioscler Thromb Vasc Biol; 2015 Mar; 35(3):637-44. PubMed ID: 25593131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiplatelet therapy in patients with diabetes mellitus.
    Grove EL; Gregersen S
    Curr Vasc Pharmacol; 2012 Jul; 10(4):494-505. PubMed ID: 22272895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet function testing and implications for clinical practice.
    Collet JP; Montalescot G
    J Cardiovasc Pharmacol Ther; 2009 Sep; 14(3):157-69. PubMed ID: 19721130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of antiplatelet agents in sepsis: a glimpse into the future.
    Akinosoglou K; Alexopoulos D
    Thromb Res; 2014 Feb; 133(2):131-8. PubMed ID: 24103487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Principal role of glycoprotein VI in alpha2beta1 and alphaIIbbeta3 activation during collagen-induced thrombus formation.
    Lecut C; Schoolmeester A; Kuijpers MJ; Broers JL; van Zandvoort MA; Vanhoorelbeke K; Deckmyn H; Jandrot-Perrus M; Heemskerk JW
    Arterioscler Thromb Vasc Biol; 2004 Sep; 24(9):1727-33. PubMed ID: 15231520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiplatelet agents.
    Varon D; Spectre G
    Hematology Am Soc Hematol Educ Program; 2009; ():267-72. PubMed ID: 20008209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelet biology and implications for antiplatelet therapy in atherothrombotic disease.
    Montalescot G
    Clin Appl Thromb Hemost; 2011 Aug; 17(4):371-80. PubMed ID: 20566574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.